Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Overview of attention for article published in BMC Cancer, September 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

blogs: 1 blog
policy: 1 policy source

twitter: 11 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 31 Mendeley

Summary Blogs Policy documents X Dimensions citations

So far, Altmetric has seen 1 blog post.

Multiple Myeloma: Health-Related QoL Maintained with Selinexor Tx for Most Patients

Physician's Weekly, 30 Dec 2021

Response seen in 1 in 4 patients in difficult to treat…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.